echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yaoming biology and tengshengbo reach an exclusive R & D cooperation for the new bispecific antibody immunotherapy

    Yaoming biology and tengshengbo reach an exclusive R & D cooperation for the new bispecific antibody immunotherapy

    • Last Update: 2018-12-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    December 10, 2018 / Meitong news agency / -- Wuxi biology, the world's leading open biopharmaceutical technology platform company, 2269 HK) announced today that it has reached strategic cooperation with bri Biosciences, a new biotech company dedicated to meet the needs of Chinese patients and public health, in the research and development of new bispecific antibodies for the treatment of infectious and immune diseases, and has become the only process development and production partner for these projects, providing strong support for Tengsheng This strategic cooperation will further speed up the expansion of product pipeline of Tengsheng boyao with the advantages of both sides According to the cooperation agreement, tengshengbo pharmaceutical is authorized to use wuxibody Gamma In China, we have found, developed and produced bispecific antibody, which is a platform for enabling the technology of pharmaceutical and biopharmaceutical integration including double antibody platform "The development of innovative immunomodulators to regulate the host immune response mechanism is still in its infancy in the world, which is expected to promote the development of infectious disease treatment." Dr Hong Zhi, co-founder and chief executive officer, said, "Yaoming bio has the world's leading technical strength in discovery, development and production of biopharmaceuticals Cooperation with such an excellent biotechnology platform company will enable Tengsheng bio to develop more innovative therapies, and transform our understanding of new targets into a key new therapy to serve the global market in China." "We're happy to include wuxibody Gamma The internal end-to-end antibody development patent technology platform empowers tengshengbo to further develop new bispecific antibodies Wuxibody, a development platform of bispecific antibody with independent intellectual property rights Gamma It not only breaks through the limitations of similar technology platforms, but also has the advantages of significantly reducing the production cost of bispecific antibodies Dr Chen Zhisheng, CEO of YaoMing bio, said, "we hope to empower partners to provide innovative bio drugs with high quality standards for more clinical urgently needed treatment areas, so as to benefit patients all over the world." About wuxibody Gamma WuXiBody Gamma It is a bispecific antibody technology platform with independent intellectual property rights, and is expected to become one of the best bispecific antibody platforms in the industry This platform has broken through the technical bottleneck of most bispecific antibody platforms, effectively overcome the challenges of low expression, high polymer and low purification yield in the development process of bispecific antibodies, and has the advantages of saving 6-18 months of R & D time for each project and significantly reducing the production cost of bispecific antibodies At present, the expression of bispecific antibody is up to 16g / L, and the purity and yield of purified protein A are over 95% Meanwhile, wuxibody Gamma The platform also has unique flexibility to build a variety of valence numbers (such as bivalent, trivalent or tetravalent bispecific antibodies) and structures to meet the biological characteristics of different projects As a Hong Kong listed company, Yaoming bio (Stock Code: 2269 HK) is the world's leading open, integrated bio pharmaceutical capability and technology enabling platform The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of June 30, 2018, 187 comprehensive projects have been developed on the platform, including 98 in the preclinical research stage, 78 in the early clinical stage (phase I, phase II), 10 in the late clinical stage (phase III) and 1 in the commercial production stage It is estimated that by 2021, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will be about 220000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.